Three months of medical cannabis did not change metabolic markers in chronic pain patients

A prospective study of 28 patients found no significant changes in blood glucose, insulin, cholesterol, cortisol, uric acid, or body weight after three months of medical cannabis use.

RTHC-03895Prospective CohortPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Prospective Cohort
Evidence
Preliminary Evidence
Sample
N=28

What This Study Found

There was no significant change in any metabolic parameter evaluated, including fasting blood glucose, hemoglobin A1c, insulin, lipid profile, cortisol, uric acid, or body weight, after three months of medical cannabis consumption.

Key Numbers

28 patients completed the study (mean age 47.8 years, ~70% female). 75% had fibromyalgia. Mean monthly consumption was 22.21 grams. 75% used extracts (oil). No significant changes in any metabolic parameter.

How They Did This

Prospective study of 28 rheumatology patients newly approved for medical cannabis for resistant chronic pain. Fasting metabolic panels and body weight were measured at baseline and three months after starting cannabis.

Why This Research Matters

Concerns about metabolic side effects could discourage patients and clinicians from using medical cannabis for chronic pain. Knowing that short-term use did not alter metabolic markers provides initial safety data.

The Bigger Picture

While cannabis affects appetite and activity levels, this small study suggests those effects may not translate into measurable metabolic changes over three months, at least in this population.

What This Study Doesn't Tell Us

Very small sample (28 patients). Only three months of follow-up. 75% used oil extracts, limiting generalizability to other consumption methods. No control group.

Questions This Raises

  • ?Would longer-term use produce metabolic changes?
  • ?Do different consumption methods or higher doses affect metabolic markers differently?

Trust & Context

Key Stat:
28 patients, 3 months, zero significant metabolic changes
Evidence Grade:
Small prospective study with no control group and short follow-up period.
Study Age:
Published in 2022.
Original Title:
Metabolic effects of medical cannabis treatment.
Published In:
Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(2), 446-448 (2022)
Database ID:
RTHC-03895

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Enrolls participants and follows them forward in time.

What do these levels mean? →

Frequently Asked Questions

Does medical cannabis affect blood sugar or cholesterol?

In this small study of 28 patients over three months, medical cannabis did not significantly change blood glucose, A1c, insulin, lipid profile, or any other metabolic marker measured.

Does medical cannabis cause weight gain?

The 28 participants showed no significant change in body weight after three months of medical cannabis use, despite cannabis's known effects on appetite.

Read More on RethinkTHC

Cite This Study

RTHC-03895·https://rethinkthc.com/research/RTHC-03895

APA

Habib, George; Aamar, Suhail. (2022). Metabolic effects of medical cannabis treatment.. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(2), 446-448. https://doi.org/10.1136/jim-2021-002059

MLA

Habib, George, et al. "Metabolic effects of medical cannabis treatment.." Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022. https://doi.org/10.1136/jim-2021-002059

RethinkTHC

RethinkTHC Research Database. "Metabolic effects of medical cannabis treatment." RTHC-03895. Retrieved from https://rethinkthc.com/research/habib-2022-metabolic-effects-of-medical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.